Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

NCT05021835 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05021835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2021
Completion date
June 9, 2026
Enrollment
6,385 (actual)
Sites
1,073

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk, chronic kidney disease, inflammation